Table 2.
Effects of resveratrol on cardiac dysfunction and heart rate in anesthetized DM mice (1 month).
| Group | HR (beats/min) | LVID (mm) | IVS (mm) | LVPW (mm) | % EF (%) | % FS (%) |
|---|---|---|---|---|---|---|
| Control | 496 ± 20 | 3.60 ± 0.23 | 0.71 ± 0.05 | 0.82 ± 0.1 | 89 ± 5 | 62 ± 4 |
| Resveratrol | 459 ± 24 | 3.58 ± 0.32 | 0.72 ± 0.04 | 0.84 ± 0.15 | 88 ± 4.0 | 58 ± 4.5 |
| DM | 440 ± 26 | 3.59 ± 0.32 | 0.74 ± 0.05 | 0.86 ± 0.17 | 78 ± 5.0∗ | 49 ± 5∗ |
| DM/resveratrol | 465 ± 24 | 3.59 ± 0.38 | 0.73 ± 0.04 | 0.85 ± 0.12 | 84 ± 5# | 55 ± 4# |
Data are presented as means ± SEM. LVID = LV end-diastolic diameter; LVPW = LV posterior wall; IVS = interventricular septum; FS = fractional shortening; EF = ejection fraction. ∗p < 0.05 versus control. #p < 0.05 versus DM group.